within Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX11_Astemizole;

model Astemizole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 2.9166666666666666e-05,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.06,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0007,
    Tlag = 600,
    Vdp = 0.03,
    k12 = 1.9055555555555555e-05,
    k21 = 1.9055555555555555e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Astemizole</td></tr><tr><td>ATC code:</td><td>R06AX11</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>60</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Astemizole is a long-acting, non-sedating antihistamine (H1-receptor antagonist) that was formerly used for the treatment of allergic conditions such as rhinitis and urticaria. Due to safety concerns, notably serious cardiac arrhythmias (QT prolongation, torsades de pointes), astemizole has been withdrawn from the market in many countries and is generally not approved for use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following single oral dose.</p><h4>References</h4><ol><li><p>Paton, DM, &amp; Webster, DR (1985). Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). <i>Clinical pharmacokinetics</i> 10(6) 477–497. DOI:<a href=\"https://doi.org/10.2165/00003088-198510060-00002\">10.2165/00003088-198510060-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2866055/\">https://pubmed.ncbi.nlm.nih.gov/2866055</a></p></li><li><p>Simons, FE, &amp; Simons, KJ (1999). Clinical pharmacology of new histamine H1 receptor antagonists. <i>Clinical pharmacokinetics</i> 36(5) 329–352. DOI:<a href=\"https://doi.org/10.2165/00003088-199936050-00003\">10.2165/00003088-199936050-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10384858/\">https://pubmed.ncbi.nlm.nih.gov/10384858</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R06AX11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Astemizole;
